Aspira Women’s Health Inc. ((AWHL)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aspira Women’s Health Inc. is conducting a study titled Deep Neural Network Stratification for the Use in Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck). The primary aim is to evaluate the clinical validity of a deep neural network algorithm, EndoCheck, which uses protein biomarker detection to aid in diagnosing endometriosis. This study holds significant potential in improving diagnostic accuracy for women suffering from chronic pelvic pain due to endometriosis.
The study is observational, with no specific interventions being tested. Instead, it focuses on using the EndoCheck algorithm to analyze serum cell-free DNA samples to validate its effectiveness as a diagnostic tool.
Designed as a case-control study with a prospective time perspective, the research does not involve any allocation or masking processes. Its primary purpose is to establish the diagnostic validity of the EndoCheck algorithm.
The study began on February 1, 2022, and is currently recruiting participants. The last update was submitted on June 23, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
The successful validation of the EndoCheck algorithm could positively impact Aspira Women’s Health’s stock performance by enhancing its product portfolio and market position. It may also influence investor sentiment positively, given the growing demand for innovative diagnostic solutions in women’s health. Competitors in the diagnostic space may need to consider similar advancements to maintain their market share.
The study is ongoing, with further details available on the ClinicalTrials portal.